Regeneron Pharmaceuticals plans to purchase 23andMe just two months after the genetics company filed for bankruptcy.

The Regeneron Biotechnology company logo is seen displayed on a smartphone ... to use large-scale genetics research to improve the way society treats and prevents illness overall." ...

At Regeneron, we have spent over three decades honing a deep expertise in disease biology and genetics. By rigorously pursuing an understanding of pathobiology—the mechanisms by which diseases ...

Regeneron bids for 23andMe at a discounted price of $256 million. The testing firm was once valued at $3.5 billion.